Crinetics Pharmaceuticals, Inc. Share Price
Equities
CRNX
US22663K1079
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.12 USD | -0.40% | -1.98% | +18.38% |
Sales 2024 * | 1.5M 120M | Sales 2025 * | 27.9M 2.23B | Capitalization | 3.32B 266B |
---|---|---|---|---|---|
Net income 2024 * | -243M -19.45B | Net income 2025 * | -270M -21.61B | EV / Sales 2024 * | 1,864 x |
Net cash position 2024 * | 523M 41.88B | Net cash position 2025 * | 457M 36.55B | EV / Sales 2025 * | 103 x |
P/E ratio 2024 * |
-12.8
x | P/E ratio 2025 * |
-11.8
x | Employees | 290 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.17% |
Latest transcript on Crinetics Pharmaceuticals, Inc.
1 day | -0.40% | ||
1 week | -1.98% | ||
Current month | -10.02% | ||
1 month | -5.20% | ||
3 months | +13.29% | ||
6 months | +48.73% | ||
Current year | +18.38% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Betz
FOU | Founder | 58 | 31/12/07 |
Scott Struthers
FOU | Founder | 62 | 31/12/07 |
Marc Wilson
DFI | Director of Finance/CFO | 45 | 31/12/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wendell Wierenga
CHM | Chairman | 76 | 30/09/15 |
Matthew Fust
BRD | Director/Board Member | 59 | 31/01/18 |
Director/Board Member | 71 | 02/09/20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 42.12 | -0.40% | 563,205 |
25/04/24 | 42.29 | -2.38% | 591,321 |
24/04/24 | 43.32 | -2.04% | 485,697 |
23/04/24 | 44.22 | +1.80% | 612,462 |
22/04/24 | 43.44 | +1.09% | 465,271 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.38% | 3.32B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CRNX Stock